IDYA
IDEAYA Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$39.78
−0.47%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 234.1M | 218.7M | 7.0M | 23.4M | 50.9M |
| Cost of Revenue | 265.3M | 314.7M | 3.8M | 4.0M | 2.1M |
| Gross Profit | (31.2M) | (96.0M) | 3.2M | 19.4M | 48.8M |
| Operating Expenses | |||||
| R&D Expense | 374.0M | 314.7M | 294.7M | 129.5M | 89.5M |
| SG&A Expense | 77.1M | 63.3M | 35.5M | 24.3M | 21.8M |
| General & Admin Expense | 77.1M | 63.3M | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (265.3M) | (314.7M) | — | — | — |
| Total Operating Expenses | 185.8M | 63.3M | 330.1M | 153.8M | 111.3M |
| Cost and Expenses | 451.1M | 378.0M | 334.0M | 157.8M | 113.4M |
| Operating Income (EBIT) | (217.0M) | (159.3M) | (327.0M) | (134.4M) | (62.5M) |
| Non-Operating | |||||
| Interest Income | 41.9M | 45.6M | 52.5M | 21.5M | 3.8M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 41.9M | 45.6M | 52.5M | 21.5M | 3.8M |
| Other Non-Op Income/Expense | 41.9M | 45.6M | 52.5M | 21.5M | 3.8M |
| Non-Operating Income (excl Interest) | — | — | (52.5M) | (21.5M) | (3.8M) |
| EBT (Pre-Tax Income) | (175.0M) | (113.7M) | (274.5M) | (113.0M) | (58.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (175.0M) | (113.7M) | (274.5M) | (113.0M) | (58.7M) |
| Earnings from Cont. Ops | (175.0M) | (113.7M) | (274.5M) | (113.0M) | (58.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (175.0M) | (113.7M) | (274.5M) | (113.0M) | (58.7M) |
| Per Share | |||||
| Basic EPS | ($1.92) | ($1.28) | ($3.36) | ($1.96) | ($1.42) |
| Diluted EPS | ($1.94) | ($1.28) | ($3.36) | ($1.96) | ($1.42) |
| Revenue Per Share | $2.54 | $2.47 | $0.09 | $0.41 | $1.23 |
| Shares | |||||
| Basic Shares Outstanding | 92.1M | 88.5M | 81.7M | 57.5M | 41.4M |
| Diluted Shares Outstanding | 92.1M | 88.5M | 81.7M | 57.5M | 41.4M |
| Profitability Metrics | |||||
| EBITDA | (212.5M) | (154.7M) | (270.6M) | (109.0M) | (56.6M) |
| D&A | 4.5M | 4.6M | 3.8M | 4.0M | 2.1M |
| EBIT | (217.0M) | (159.3M) | (274.5M) | (113.0M) | (58.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026